Trulicity vs. Zepbound
Trulicity and Zepbound share a GLP-1 agonist mechanism but target different conditions. Also, Zepbound is a GIP receptor agonist, too. Trulicity is primarily for type 2 diabetes management and cardiovascular risk reduction, while Zepbound focuses on chronic weight management. Trulicity achieves HbA1c reductions and modest weight loss, whereas Zepbound delivers more substantial weight loss. Both share nausea as a common side effect, with overlapping risks such as pancreatitis. Trulicity costs $875/month, while Zepbound’s cost is $1,125/month. Neither drug faces current shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, fatigue, and decreased appetite.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions